Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) - Net Assets
Based on the latest financial reports, Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) has net assets worth CN¥4.13 Billion CNY (≈ $603.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.17 Billion ≈ $756.15 Million USD) and total liabilities (CN¥1.04 Billion ≈ $152.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangdong Zhongsheng Pharmaceutical Co L liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.13 Billion |
| % of Total Assets | 79.84% |
| Annual Growth Rate | 20.55% |
| 5-Year Change | 10.58% |
| 10-Year Change | 90.09% |
| Growth Volatility | 147.93 |
Guangdong Zhongsheng Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Guangdong Zhongsheng Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Guangdong Zhongsheng Pharmaceutical Co L total assets for the complete picture of this company's asset base.
Annual Net Assets for Guangdong Zhongsheng Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Guangdong Zhongsheng Pharmaceutical Co Ltd from 2006 to 2024. For live valuation and market cap data, see 002317 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.01 Billion ≈ $586.81 Million |
-11.39% |
| 2023-12-31 | CN¥4.53 Billion ≈ $662.25 Million |
+18.58% |
| 2022-12-31 | CN¥3.82 Billion ≈ $558.47 Million |
+7.87% |
| 2021-12-31 | CN¥3.54 Billion ≈ $517.74 Million |
-2.44% |
| 2020-12-31 | CN¥3.63 Billion ≈ $530.67 Million |
-12.29% |
| 2019-12-31 | CN¥4.13 Billion ≈ $605.00 Million |
+4.65% |
| 2018-12-31 | CN¥3.95 Billion ≈ $578.14 Million |
+5.91% |
| 2017-12-31 | CN¥3.73 Billion ≈ $545.87 Million |
+8.94% |
| 2016-12-31 | CN¥3.42 Billion ≈ $501.07 Million |
+62.32% |
| 2015-12-31 | CN¥2.11 Billion ≈ $308.69 Million |
+11.10% |
| 2014-12-31 | CN¥1.90 Billion ≈ $277.85 Million |
+8.94% |
| 2013-12-31 | CN¥1.74 Billion ≈ $255.05 Million |
+9.85% |
| 2012-12-31 | CN¥1.59 Billion ≈ $232.18 Million |
+7.41% |
| 2011-12-31 | CN¥1.48 Billion ≈ $216.16 Million |
+6.53% |
| 2010-12-31 | CN¥1.39 Billion ≈ $202.91 Million |
+7.07% |
| 2009-12-31 | CN¥1.30 Billion ≈ $189.52 Million |
+651.26% |
| 2008-12-31 | CN¥172.40 Million ≈ $25.23 Million |
+32.04% |
| 2007-12-31 | CN¥130.56 Million ≈ $19.11 Million |
-5.88% |
| 2006-12-31 | CN¥138.72 Million ≈ $20.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Zhongsheng Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1370.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥915.41 Million | 23.38% |
| Common Stock | CN¥851.56 Million | 21.75% |
| Other Components | CN¥2.15 Billion | 54.86% |
| Total Equity | CN¥3.91 Billion | 100.00% |
Guangdong Zhongsheng Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Zhongsheng Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SK Bioscience Co Ltd
KO:302440
|
$2.29 Billion |
|
Ecopro Co. Ltd
KQ:086520
|
$2.29 Billion |
|
Azelis Group NV
BR:AZE
|
$2.29 Billion |
|
Hanesbrands Inc
NYSE:HBI
|
$2.29 Billion |
|
Guangdong Advertising Co Ltd
SHE:002400
|
$2.29 Billion |
|
Beijing TRS Information Tech
SHE:300229
|
$2.28 Billion |
|
ISC Co. Ltd
KQ:095340
|
$2.28 Billion |
|
Now Inc
NYSE:DNOW
|
$2.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Zhongsheng Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,356,304,632 to 3,914,773,066, a change of -441,531,566 (-10.1%).
- Net loss of 299,157,112 reduced equity.
- Dividend payments of 170,953,595 reduced retained earnings.
- Share repurchases of 8,934,120 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-299.16 Million | -7.64% |
| Dividends Paid | CN¥170.95 Million | -4.37% |
| Share Repurchases | CN¥8.93 Million | -0.23% |
| Other Changes | CN¥37.51 Million | +0.96% |
| Total Change | CN¥- | -10.14% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Zhongsheng Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 77.53x to 3.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.24 | CN¥18.39 | x |
| 2007-12-31 | CN¥0.22 | CN¥18.39 | x |
| 2008-12-31 | CN¥0.32 | CN¥18.39 | x |
| 2009-12-31 | CN¥2.41 | CN¥18.39 | x |
| 2010-12-31 | CN¥1.92 | CN¥18.39 | x |
| 2011-12-31 | CN¥2.06 | CN¥18.39 | x |
| 2012-12-31 | CN¥2.19 | CN¥18.39 | x |
| 2013-12-31 | CN¥2.33 | CN¥18.39 | x |
| 2014-12-31 | CN¥2.55 | CN¥18.39 | x |
| 2015-12-31 | CN¥2.78 | CN¥18.39 | x |
| 2016-12-31 | CN¥4.42 | CN¥18.39 | x |
| 2017-12-31 | CN¥4.59 | CN¥18.39 | x |
| 2018-12-31 | CN¥4.75 | CN¥18.39 | x |
| 2019-12-31 | CN¥5.06 | CN¥18.39 | x |
| 2020-12-31 | CN¥4.39 | CN¥18.39 | x |
| 2021-12-31 | CN¥4.36 | CN¥18.39 | x |
| 2022-12-31 | CN¥4.60 | CN¥18.39 | x |
| 2023-12-31 | CN¥5.29 | CN¥18.39 | x |
| 2024-12-31 | CN¥4.71 | CN¥18.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Zhongsheng Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.12%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.42x
- Recent ROE (-7.64%) is below the historical average (11.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 24.74% | 9.75% | 1.12x | 2.26x | CN¥18.99 Million |
| 2007 | 35.51% | 10.45% | 1.36x | 2.50x | CN¥30.36 Million |
| 2008 | 43.15% | 15.36% | 1.54x | 1.83x | CN¥57.14 Million |
| 2009 | 7.75% | 18.19% | 0.39x | 1.08x | CN¥-29.16 Million |
| 2010 | 9.48% | 20.53% | 0.43x | 1.07x | CN¥-7.16 Million |
| 2011 | 10.19% | 20.29% | 0.47x | 1.06x | CN¥2.82 Million |
| 2012 | 11.44% | 20.48% | 0.51x | 1.09x | CN¥22.84 Million |
| 2013 | 11.14% | 17.22% | 0.55x | 1.18x | CN¥19.26 Million |
| 2014 | 12.15% | 17.16% | 0.57x | 1.25x | CN¥39.68 Million |
| 2015 | 14.40% | 18.81% | 0.47x | 1.62x | CN¥90.60 Million |
| 2016 | 12.21% | 24.48% | 0.40x | 1.24x | CN¥74.90 Million |
| 2017 | 11.33% | 21.39% | 0.40x | 1.31x | CN¥49.41 Million |
| 2018 | 11.16% | 18.45% | 0.45x | 1.34x | CN¥45.35 Million |
| 2019 | 7.81% | 12.55% | 0.46x | 1.35x | CN¥-88.86 Million |
| 2020 | -12.10% | -22.50% | 0.40x | 1.35x | CN¥-779.10 Million |
| 2021 | 7.99% | 11.43% | 0.50x | 1.41x | CN¥-69.93 Million |
| 2022 | 8.70% | 12.03% | 0.46x | 1.56x | CN¥-48.22 Million |
| 2023 | 6.04% | 10.08% | 0.40x | 1.48x | CN¥-172.36 Million |
| 2024 | -7.64% | -12.12% | 0.44x | 1.42x | CN¥-690.63 Million |
Industry Comparison
This section compares Guangdong Zhongsheng Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Zhongsheng Pharmaceutical Co Ltd (002317) | CN¥4.13 Billion | 24.74% | 0.25x | $2.29 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China. The company offers traditional Chinese medicine and chemical medicine. It also focuses on the fields of cardiovascular, respiratory, ophthalmology, and digestive. Guangdong Zhongsheng Pharmaceutical Co., Ltd. was founded in 1979 and is based in Dongguan, China.